Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
Background: An allogeneic antitumour effect has been reported for various cancers. We evaluated the experience of allogeneic haematopoietic stem cell transplantation (HSCT) for renal cell carcinoma (RCC) in 124 patients from 21 European centres. Patients and methods: Reduced intensity conditioning a...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2006-07, Vol.17 (7), p.1134-1140 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1140 |
|---|---|
| container_issue | 7 |
| container_start_page | 1134 |
| container_title | Annals of oncology |
| container_volume | 17 |
| creator | Barkholt, L. Bregni, M. Remberger, M. Blaise, D. Peccatori, J. Massenkeil, G. Pedrazzoli, P. Zambelli, A. Bay, J.-O. Francois, S. Martino, R. Bengala, C. Brune, M. Lenhoff, S. Porcellini, A. Falda, M. Siena, S. Demirer, T. Niederwieser, D. Ringdén, O. |
| description | Background: An allogeneic antitumour effect has been reported for various cancers. We evaluated the experience of allogeneic haematopoietic stem cell transplantation (HSCT) for renal cell carcinoma (RCC) in 124 patients from 21 European centres.
Patients and methods: Reduced intensity conditioning and peripheral blood stem cells from an HLA-identical sibling (n = 106), a mismatched related (n = 5), or an unrelated (n = 13) donor were used. Immunosuppression was cyclosporine alone, or combined with methotrexate or mycophenolate mofetil. Donor lymphocyte infusions (DLI) were given to 42 patients. The median follow-up was 15 (range 3–41) months.
Results: All but three patients engrafted. The cumulative incidence of moderate to severe, grades II–IV acute GVHD was 40% and for chronic GVHD it was 33%. Transplant-related mortality was 16% at one year. Complete (n = 4) or partial (n = 24) responses, median 150 (range 42–600) days post-transplant, were associated with time from diagnosis to HSCT, mismatched donor and acute GVHD II-IV. Factors associated with survival included chronic GVHD (hazards ratio, HR 4.12, P < 0.001), DLI (HR 3.39, P < 0.001), 70 (HR 2.33, P = 0.03). Patients (n = 17) with chronic GVHD and given DLI had a 2-year survival of 70%.
Conclusion: Patients with metastatic RCC, less than three metastatic locations and a Karnofsky score >70% can be considered for HSCT. Posttransplant DLI and limited chronic GVHD improved the patient survival. |
| doi_str_mv | 10.1093/annonc/mdl086 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_575827</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419453854</els_id><sourcerecordid>17273961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c659t-6336adeddeb773139730e9e936401ffe39a7ee46ba976c2f714306231b5dbaf53</originalsourceid><addsrcrecordid>eNqFktuL1DAUxoso7rj66KsUQd_qJk1ze1yW1RVmFW8gIoTT9FSz2ybdpPXy35thxh0QBh9CcpLfd05O8hXFY0peUKLZCXgfvD0Zu4EocadYUS50pUhD7xYromtWSc6ao-JBSleEEKFrfb84okI0imqxKr6eDkP4hh6dLb8DjjCHKTicc5hmHEuLw1DOEXyaBvAzzC74sg-xHHGGtIltGdHDUFqI1vkwQul8eb7EMOHD4l4PQ8JHu_m4-PTy_OPZRbV---r12em6soLruRKMCeiw67CVklGmJSOoUTPRENr3yDRIxEa0oKWwdS9pw4ioGW1510LP2XFRbfOmnzgtrZmiGyH-NgGc2W1d5xUaLrmqZeblQX6KoduL_gqp5oJonZXrg8phmfJo89go0CpQPVhTQ61M02lhVMOpabiSnEjRM-xzuufbdLnqzYJpNqNLmycHj2FJRigupCTyvyCVuS0taAaf_gNehSXm_8mMFqLmgtf797IxpBSxv-2DErNxldm6ymxdlfknu6RLO2K3p3c2ysCzHQDJwtBnv1iX9pwipK652hd22Vy_bs8hXhshmeTm4vMX8-byw3st3l0avv8ozO754TCaZB16i52LaGfTBXfgyn8A8bb8Qg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196625652</pqid></control><display><type>article</type><title>Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SWEPUB Freely available online</source><source>Alma/SFX Local Collection</source><creator>Barkholt, L. ; Bregni, M. ; Remberger, M. ; Blaise, D. ; Peccatori, J. ; Massenkeil, G. ; Pedrazzoli, P. ; Zambelli, A. ; Bay, J.-O. ; Francois, S. ; Martino, R. ; Bengala, C. ; Brune, M. ; Lenhoff, S. ; Porcellini, A. ; Falda, M. ; Siena, S. ; Demirer, T. ; Niederwieser, D. ; Ringdén, O.</creator><creatorcontrib>Barkholt, L. ; Bregni, M. ; Remberger, M. ; Blaise, D. ; Peccatori, J. ; Massenkeil, G. ; Pedrazzoli, P. ; Zambelli, A. ; Bay, J.-O. ; Francois, S. ; Martino, R. ; Bengala, C. ; Brune, M. ; Lenhoff, S. ; Porcellini, A. ; Falda, M. ; Siena, S. ; Demirer, T. ; Niederwieser, D. ; Ringdén, O. ; On behalf of the French ITAC group and the EBMT Solid Tumour Working Party ; French ITAC group and the EBMT Solid Tumour Working Party</creatorcontrib><description>Background: An allogeneic antitumour effect has been reported for various cancers. We evaluated the experience of allogeneic haematopoietic stem cell transplantation (HSCT) for renal cell carcinoma (RCC) in 124 patients from 21 European centres.
Patients and methods: Reduced intensity conditioning and peripheral blood stem cells from an HLA-identical sibling (n = 106), a mismatched related (n = 5), or an unrelated (n = 13) donor were used. Immunosuppression was cyclosporine alone, or combined with methotrexate or mycophenolate mofetil. Donor lymphocyte infusions (DLI) were given to 42 patients. The median follow-up was 15 (range 3–41) months.
Results: All but three patients engrafted. The cumulative incidence of moderate to severe, grades II–IV acute GVHD was 40% and for chronic GVHD it was 33%. Transplant-related mortality was 16% at one year. Complete (n = 4) or partial (n = 24) responses, median 150 (range 42–600) days post-transplant, were associated with time from diagnosis to HSCT, mismatched donor and acute GVHD II-IV. Factors associated with survival included chronic GVHD (hazards ratio, HR 4.12, P < 0.001), DLI (HR 3.39, P < 0.001), <3 metastatic sites (HR 2.61, P = 0.002) and a Karnofsky score >70 (HR 2.33, P = 0.03). Patients (n = 17) with chronic GVHD and given DLI had a 2-year survival of 70%.
Conclusion: Patients with metastatic RCC, less than three metastatic locations and a Karnofsky score >70% can be considered for HSCT. Posttransplant DLI and limited chronic GVHD improved the patient survival.</description><identifier>ISSN: 0923-7534</identifier><identifier>ISSN: 1569-8041</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdl086</identifier><identifier>PMID: 16648196</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Aged ; allogeneic stem cell transplantation ; Antineoplastic agents ; antitumour effect ; Biological and medical sciences ; Cancer and Oncology ; Cancer och onkologi ; Carcinoma, Renal Cell - mortality ; Carcinoma, Renal Cell - secondary ; Carcinoma, Renal Cell - therapy ; Chimerism ; Clinical Medicine ; Europe ; Female ; Graft vs Host Disease - epidemiology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic Stem Cell Transplantation - mortality ; Humans ; Immunosuppression - methods ; intensity conditioning ; Kidney Neoplasms - mortality ; Kidney Neoplasms - pathology ; Kidney Neoplasms - therapy ; Kidneys ; Klinisk medicin ; Male ; Medical and Health Sciences ; Medical sciences ; Medicin och hälsovetenskap ; Middle Aged ; Neoplasm Metastasis - prevention & control ; Neoplasm Metastasis - therapy ; Nephrology. Urinary tract diseases ; Patient Selection ; Pharmacology. Drug treatments ; reduced ; reduced intensity conditioning ; renal cell carcinoma ; Survival Analysis ; Transplantation Conditioning ; Tumors of the urinary system</subject><ispartof>Annals of oncology, 2006-07, Vol.17 (7), p.1134-1140</ispartof><rights>2006 European Society for Medical Oncology</rights><rights>2006 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Jul 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c659t-6336adeddeb773139730e9e936401ffe39a7ee46ba976c2f714306231b5dbaf53</citedby><cites>FETCH-LOGICAL-c659t-6336adeddeb773139730e9e936401ffe39a7ee46ba976c2f714306231b5dbaf53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,554,782,786,887,27933,27934</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18002258$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16648196$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/404247$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1956099$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Barkholt, L.</creatorcontrib><creatorcontrib>Bregni, M.</creatorcontrib><creatorcontrib>Remberger, M.</creatorcontrib><creatorcontrib>Blaise, D.</creatorcontrib><creatorcontrib>Peccatori, J.</creatorcontrib><creatorcontrib>Massenkeil, G.</creatorcontrib><creatorcontrib>Pedrazzoli, P.</creatorcontrib><creatorcontrib>Zambelli, A.</creatorcontrib><creatorcontrib>Bay, J.-O.</creatorcontrib><creatorcontrib>Francois, S.</creatorcontrib><creatorcontrib>Martino, R.</creatorcontrib><creatorcontrib>Bengala, C.</creatorcontrib><creatorcontrib>Brune, M.</creatorcontrib><creatorcontrib>Lenhoff, S.</creatorcontrib><creatorcontrib>Porcellini, A.</creatorcontrib><creatorcontrib>Falda, M.</creatorcontrib><creatorcontrib>Siena, S.</creatorcontrib><creatorcontrib>Demirer, T.</creatorcontrib><creatorcontrib>Niederwieser, D.</creatorcontrib><creatorcontrib>Ringdén, O.</creatorcontrib><creatorcontrib>On behalf of the French ITAC group and the EBMT Solid Tumour Working Party</creatorcontrib><creatorcontrib>French ITAC group and the EBMT Solid Tumour Working Party</creatorcontrib><title>Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: An allogeneic antitumour effect has been reported for various cancers. We evaluated the experience of allogeneic haematopoietic stem cell transplantation (HSCT) for renal cell carcinoma (RCC) in 124 patients from 21 European centres.
Patients and methods: Reduced intensity conditioning and peripheral blood stem cells from an HLA-identical sibling (n = 106), a mismatched related (n = 5), or an unrelated (n = 13) donor were used. Immunosuppression was cyclosporine alone, or combined with methotrexate or mycophenolate mofetil. Donor lymphocyte infusions (DLI) were given to 42 patients. The median follow-up was 15 (range 3–41) months.
Results: All but three patients engrafted. The cumulative incidence of moderate to severe, grades II–IV acute GVHD was 40% and for chronic GVHD it was 33%. Transplant-related mortality was 16% at one year. Complete (n = 4) or partial (n = 24) responses, median 150 (range 42–600) days post-transplant, were associated with time from diagnosis to HSCT, mismatched donor and acute GVHD II-IV. Factors associated with survival included chronic GVHD (hazards ratio, HR 4.12, P < 0.001), DLI (HR 3.39, P < 0.001), <3 metastatic sites (HR 2.61, P = 0.002) and a Karnofsky score >70 (HR 2.33, P = 0.03). Patients (n = 17) with chronic GVHD and given DLI had a 2-year survival of 70%.
Conclusion: Patients with metastatic RCC, less than three metastatic locations and a Karnofsky score >70% can be considered for HSCT. Posttransplant DLI and limited chronic GVHD improved the patient survival.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>allogeneic stem cell transplantation</subject><subject>Antineoplastic agents</subject><subject>antitumour effect</subject><subject>Biological and medical sciences</subject><subject>Cancer and Oncology</subject><subject>Cancer och onkologi</subject><subject>Carcinoma, Renal Cell - mortality</subject><subject>Carcinoma, Renal Cell - secondary</subject><subject>Carcinoma, Renal Cell - therapy</subject><subject>Chimerism</subject><subject>Clinical Medicine</subject><subject>Europe</subject><subject>Female</subject><subject>Graft vs Host Disease - epidemiology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic Stem Cell Transplantation - mortality</subject><subject>Humans</subject><subject>Immunosuppression - methods</subject><subject>intensity conditioning</subject><subject>Kidney Neoplasms - mortality</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidney Neoplasms - therapy</subject><subject>Kidneys</subject><subject>Klinisk medicin</subject><subject>Male</subject><subject>Medical and Health Sciences</subject><subject>Medical sciences</subject><subject>Medicin och hälsovetenskap</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis - prevention & control</subject><subject>Neoplasm Metastasis - therapy</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Patient Selection</subject><subject>Pharmacology. Drug treatments</subject><subject>reduced</subject><subject>reduced intensity conditioning</subject><subject>renal cell carcinoma</subject><subject>Survival Analysis</subject><subject>Transplantation Conditioning</subject><subject>Tumors of the urinary system</subject><issn>0923-7534</issn><issn>1569-8041</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNqFktuL1DAUxoso7rj66KsUQd_qJk1ze1yW1RVmFW8gIoTT9FSz2ybdpPXy35thxh0QBh9CcpLfd05O8hXFY0peUKLZCXgfvD0Zu4EocadYUS50pUhD7xYromtWSc6ao-JBSleEEKFrfb84okI0imqxKr6eDkP4hh6dLb8DjjCHKTicc5hmHEuLw1DOEXyaBvAzzC74sg-xHHGGtIltGdHDUFqI1vkwQul8eb7EMOHD4l4PQ8JHu_m4-PTy_OPZRbV---r12em6soLruRKMCeiw67CVklGmJSOoUTPRENr3yDRIxEa0oKWwdS9pw4ioGW1510LP2XFRbfOmnzgtrZmiGyH-NgGc2W1d5xUaLrmqZeblQX6KoduL_gqp5oJonZXrg8phmfJo89go0CpQPVhTQ61M02lhVMOpabiSnEjRM-xzuufbdLnqzYJpNqNLmycHj2FJRigupCTyvyCVuS0taAaf_gNehSXm_8mMFqLmgtf797IxpBSxv-2DErNxldm6ymxdlfknu6RLO2K3p3c2ysCzHQDJwtBnv1iX9pwipK652hd22Vy_bs8hXhshmeTm4vMX8-byw3st3l0avv8ozO754TCaZB16i52LaGfTBXfgyn8A8bb8Qg</recordid><startdate>20060701</startdate><enddate>20060701</enddate><creator>Barkholt, L.</creator><creator>Bregni, M.</creator><creator>Remberger, M.</creator><creator>Blaise, D.</creator><creator>Peccatori, J.</creator><creator>Massenkeil, G.</creator><creator>Pedrazzoli, P.</creator><creator>Zambelli, A.</creator><creator>Bay, J.-O.</creator><creator>Francois, S.</creator><creator>Martino, R.</creator><creator>Bengala, C.</creator><creator>Brune, M.</creator><creator>Lenhoff, S.</creator><creator>Porcellini, A.</creator><creator>Falda, M.</creator><creator>Siena, S.</creator><creator>Demirer, T.</creator><creator>Niederwieser, D.</creator><creator>Ringdén, O.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>6I.</scope><scope>AAFTH</scope><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AGCHP</scope><scope>AOWAS</scope><scope>D8T</scope><scope>D95</scope><scope>ZZAVC</scope></search><sort><creationdate>20060701</creationdate><title>Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe</title><author>Barkholt, L. ; Bregni, M. ; Remberger, M. ; Blaise, D. ; Peccatori, J. ; Massenkeil, G. ; Pedrazzoli, P. ; Zambelli, A. ; Bay, J.-O. ; Francois, S. ; Martino, R. ; Bengala, C. ; Brune, M. ; Lenhoff, S. ; Porcellini, A. ; Falda, M. ; Siena, S. ; Demirer, T. ; Niederwieser, D. ; Ringdén, O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c659t-6336adeddeb773139730e9e936401ffe39a7ee46ba976c2f714306231b5dbaf53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>allogeneic stem cell transplantation</topic><topic>Antineoplastic agents</topic><topic>antitumour effect</topic><topic>Biological and medical sciences</topic><topic>Cancer and Oncology</topic><topic>Cancer och onkologi</topic><topic>Carcinoma, Renal Cell - mortality</topic><topic>Carcinoma, Renal Cell - secondary</topic><topic>Carcinoma, Renal Cell - therapy</topic><topic>Chimerism</topic><topic>Clinical Medicine</topic><topic>Europe</topic><topic>Female</topic><topic>Graft vs Host Disease - epidemiology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic Stem Cell Transplantation - mortality</topic><topic>Humans</topic><topic>Immunosuppression - methods</topic><topic>intensity conditioning</topic><topic>Kidney Neoplasms - mortality</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidney Neoplasms - therapy</topic><topic>Kidneys</topic><topic>Klinisk medicin</topic><topic>Male</topic><topic>Medical and Health Sciences</topic><topic>Medical sciences</topic><topic>Medicin och hälsovetenskap</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis - prevention & control</topic><topic>Neoplasm Metastasis - therapy</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Patient Selection</topic><topic>Pharmacology. Drug treatments</topic><topic>reduced</topic><topic>reduced intensity conditioning</topic><topic>renal cell carcinoma</topic><topic>Survival Analysis</topic><topic>Transplantation Conditioning</topic><topic>Tumors of the urinary system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barkholt, L.</creatorcontrib><creatorcontrib>Bregni, M.</creatorcontrib><creatorcontrib>Remberger, M.</creatorcontrib><creatorcontrib>Blaise, D.</creatorcontrib><creatorcontrib>Peccatori, J.</creatorcontrib><creatorcontrib>Massenkeil, G.</creatorcontrib><creatorcontrib>Pedrazzoli, P.</creatorcontrib><creatorcontrib>Zambelli, A.</creatorcontrib><creatorcontrib>Bay, J.-O.</creatorcontrib><creatorcontrib>Francois, S.</creatorcontrib><creatorcontrib>Martino, R.</creatorcontrib><creatorcontrib>Bengala, C.</creatorcontrib><creatorcontrib>Brune, M.</creatorcontrib><creatorcontrib>Lenhoff, S.</creatorcontrib><creatorcontrib>Porcellini, A.</creatorcontrib><creatorcontrib>Falda, M.</creatorcontrib><creatorcontrib>Siena, S.</creatorcontrib><creatorcontrib>Demirer, T.</creatorcontrib><creatorcontrib>Niederwieser, D.</creatorcontrib><creatorcontrib>Ringdén, O.</creatorcontrib><creatorcontrib>On behalf of the French ITAC group and the EBMT Solid Tumour Working Party</creatorcontrib><creatorcontrib>French ITAC group and the EBMT Solid Tumour Working Party</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SWEPUB Lunds universitet full text</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Lunds universitet</collection><collection>SwePub Articles full text</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barkholt, L.</au><au>Bregni, M.</au><au>Remberger, M.</au><au>Blaise, D.</au><au>Peccatori, J.</au><au>Massenkeil, G.</au><au>Pedrazzoli, P.</au><au>Zambelli, A.</au><au>Bay, J.-O.</au><au>Francois, S.</au><au>Martino, R.</au><au>Bengala, C.</au><au>Brune, M.</au><au>Lenhoff, S.</au><au>Porcellini, A.</au><au>Falda, M.</au><au>Siena, S.</au><au>Demirer, T.</au><au>Niederwieser, D.</au><au>Ringdén, O.</au><aucorp>On behalf of the French ITAC group and the EBMT Solid Tumour Working Party</aucorp><aucorp>French ITAC group and the EBMT Solid Tumour Working Party</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2006-07-01</date><risdate>2006</risdate><volume>17</volume><issue>7</issue><spage>1134</spage><epage>1140</epage><pages>1134-1140</pages><issn>0923-7534</issn><issn>1569-8041</issn><eissn>1569-8041</eissn><abstract>Background: An allogeneic antitumour effect has been reported for various cancers. We evaluated the experience of allogeneic haematopoietic stem cell transplantation (HSCT) for renal cell carcinoma (RCC) in 124 patients from 21 European centres.
Patients and methods: Reduced intensity conditioning and peripheral blood stem cells from an HLA-identical sibling (n = 106), a mismatched related (n = 5), or an unrelated (n = 13) donor were used. Immunosuppression was cyclosporine alone, or combined with methotrexate or mycophenolate mofetil. Donor lymphocyte infusions (DLI) were given to 42 patients. The median follow-up was 15 (range 3–41) months.
Results: All but three patients engrafted. The cumulative incidence of moderate to severe, grades II–IV acute GVHD was 40% and for chronic GVHD it was 33%. Transplant-related mortality was 16% at one year. Complete (n = 4) or partial (n = 24) responses, median 150 (range 42–600) days post-transplant, were associated with time from diagnosis to HSCT, mismatched donor and acute GVHD II-IV. Factors associated with survival included chronic GVHD (hazards ratio, HR 4.12, P < 0.001), DLI (HR 3.39, P < 0.001), <3 metastatic sites (HR 2.61, P = 0.002) and a Karnofsky score >70 (HR 2.33, P = 0.03). Patients (n = 17) with chronic GVHD and given DLI had a 2-year survival of 70%.
Conclusion: Patients with metastatic RCC, less than three metastatic locations and a Karnofsky score >70% can be considered for HSCT. Posttransplant DLI and limited chronic GVHD improved the patient survival.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>16648196</pmid><doi>10.1093/annonc/mdl086</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2006-07, Vol.17 (7), p.1134-1140 |
| issn | 0923-7534 1569-8041 1569-8041 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_575827 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SWEPUB Freely available online; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged allogeneic stem cell transplantation Antineoplastic agents antitumour effect Biological and medical sciences Cancer and Oncology Cancer och onkologi Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - secondary Carcinoma, Renal Cell - therapy Chimerism Clinical Medicine Europe Female Graft vs Host Disease - epidemiology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cell Transplantation - mortality Humans Immunosuppression - methods intensity conditioning Kidney Neoplasms - mortality Kidney Neoplasms - pathology Kidney Neoplasms - therapy Kidneys Klinisk medicin Male Medical and Health Sciences Medical sciences Medicin och hälsovetenskap Middle Aged Neoplasm Metastasis - prevention & control Neoplasm Metastasis - therapy Nephrology. Urinary tract diseases Patient Selection Pharmacology. Drug treatments reduced reduced intensity conditioning renal cell carcinoma Survival Analysis Transplantation Conditioning Tumors of the urinary system |
| title | Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T23%3A08%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Allogeneic%20haematopoietic%20stem%20cell%20transplantation%20for%20metastatic%20renal%20carcinoma%20in%20Europe&rft.jtitle=Annals%20of%20oncology&rft.au=Barkholt,%20L.&rft.aucorp=On%20behalf%20of%20the%20French%20ITAC%20group%20and%20the%20EBMT%20Solid%20Tumour%20Working%20Party&rft.date=2006-07-01&rft.volume=17&rft.issue=7&rft.spage=1134&rft.epage=1140&rft.pages=1134-1140&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdl086&rft_dat=%3Cproquest_swepu%3E17273961%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196625652&rft_id=info:pmid/16648196&rft_els_id=S0923753419453854&rfr_iscdi=true |